Animal health products manufacturer Phibro Animal Health (NASDAQ: PAHC) will be reporting earnings this Wednesday afternoon. Here’s what investors should know.

Phibro Animal Health beat analysts’ revenue expectations last quarter, reporting revenues of $383.5 million, up 10.3% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and full-year EPS guidance in line with analysts’ estimates.

Is Phibro Animal Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Phibro Animal Health’s revenue to decline 1.9% year on year, a reversal from the 38.6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Phibro Animal Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Phibro Animal Health’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corcept delivered year-on-year revenue growth of 31.7%, beating analysts’ expectations by 21.6%, and Bristol-Myers Squibb reported revenues up 5.7%, topping estimates by 12.9%. Corcept traded up 27.3% following the results while Bristol-Myers Squibb was also up 3.5%.

Read our full analysis of Corcept’s results here and Bristol-Myers Squibb’s results here.

There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 6.8% on average over the last month. Phibro Animal Health’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $45 (compared to the current share price of $35.30).

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.